August 2003
Worldwide Biotech;Aug2003, Vol. 15 Issue 8, p7
Trade Publication
Reports on the planned collaboration of Peregrine Pharmaceuticals Inc. and Affitech AS for the production of human antibodies for Peregrine's Vascular Targeting Agent and antigiogenesis programs.


Related Articles

  • PEREGRINE INITIATES ANTIBODY GENERATION AGAINST 2 TARGETS.  // Biotech Business;Feb2002, Vol. 15 Issue 2, p3 

    No abstract available.

  • Peregrine Builds Up Technology and Drug Pipeline. Mirasol, Feliza // Chemical Market Reporter;1/31/2005, Vol. 267 Issue 5, p7 

    This article reports that Peregrine Pharmaceuticals Inc. last week signed a deal allowing it to tap into Merck KGaA's protein expression expertise for the purpose of developing product candidates. Under the collaboration, Peregrine will use Merck's protein expression technologies, developed by...

  • R&D News Headlines February 15, 2003 - March 14, 2004.  // PharmaWatch: Biotechnology;May 2004, Vol. 3 Issue 5, p6 

    Reports global developments related to biotechnology research and development as of March 2004. Results of the antiviral study by LipidViro Tech; Inhibition of breast cancer growth by antibody from Peregrine; Enhancement of efficacy of cancer chemotherapy with OncoVex from BioVex Ltd.

  • Peregrine antibody used in combination therapy inhibits breast cancer growth by 93%.  // PharmaWatch: Biotechnology;May 2004, Vol. 3 Issue 5, p6 

    Focuses on the presentation of preclinical data demonstrating the enhancement of efficacy of chemotherapy methods with anti-phospholipid antibody 3G4 from Peregrine Pharmaceuticals Inc. Combination of 3G4 and Docetaxel; Effectiveness of the treatment against breast cancer; Rate of inhibition of...

  • Phase II Update Triggers Wild Ride for Peregrine.  // Bioworld Week;6/1/2009, Vol. 17 Issue 22, p4 

    The article reports that shares of Peregrine Pharmaceuticals Inc. has skyrocketed after reports of the progress of its Phase II brain cancer drug on May 28, 2009. It states that the company has gained nearly 95% growth shares, 35 cents up compared to the same period in 2008. It states that the...

  • Peregrine Seals $44.4M DoD Deal After Budget Detour. Young, Donna // BioWorld Today;7/2/2008, Vol. 19 Issue 128, p1 

    The article reports that Peregrine Pharmaceuticals has closed a deal with the U.S. Department of Defense in July 2008 for the development and testing of bavituximab. Said antibody is a potential treatment for viral hemorrhagic fever infections such as Ebola. Also the antibody has been shown to...

  • Financings Roundup.  // BioWorld Today;7/15/2010, Vol. 21 Issue 135, p6 

    The article reports on the 109 million U.S. dollars raised by Peregrine Pharmaceuticals Inc. in its Series F financing round to be used to prepare for the commercialization of the PacBio RS system.

  • Financings Roundup.  // BioWorld Today;9/6/2011, Vol. 22 Issue 172, p2 

    This section offers news briefs related to financings of biopharmaceutical companies, including a non-brokered private placement by Pacgen Biopharmaceuticals Corp. that raised a total of 300,000 Canadian dollars, and a registered direct offering of 6.25 million shares by Peregrine...

  • AACR 2012.  // BioWorld Today;4/5/2012, Vol. 23 Issue 66, p7 

    The article presents an overview of findings from two Phase 1 trials of bavitixmab, a phosphatidylserine-targeting monoclonal antibody from Peregrine Pharmaceuticals Inc.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics